Abstract
Ovarian high-grade serous carcinoma (HGSC) is the most frequent histologic type of ovarian cancer. In the past 15 years, the discovery of PARP inhibitors has changed ovarian cancer treatment in different clinical settings.About 20% of HGSC present CCNE1 amplification (amp), a gene that encodes cyclin E1, a central regulator of cell cycle and DNA replication. Despite the relative success o…